The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American ...

And according to the company's 10Q filing, "the majority of our online revenue is subscription ... tirzepatide -- the main ingredient in Mounjaro and Zepbound -- from its shortage list.

Mounjaro is a GLP-1 inhibitor developed to help people with diabetes regulate their blood glucose. Elon Musk, the 53-year-old CEO of Tesla and SpaceX, recently shared a festive image of himself ...

tirzepatide — the active ingredient in Zepbound and its counterpart Mounjaro for diabetes — is fully available again. "FDA has determined that the shortage of tirzepatide injection products ...

agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are used for either diabetes treatment or chronic weight management. Where to invest $1,000 right now? Our analyst team ...

In the same vein, Lilly's Mounjaro is approved by the FDA for diabetes, while its sibling treatment, Zepbound ... Lilly's progress against Wegovy -- combined with its diverse and growing medical ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound ... Moderna's, and J's combined! Moreover, ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...